PriceTargets.com logo

GE HealthCare Technologies - GEHC Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $92.50
  • Forecasted Upside: 17.61%
  • Number of Analysts: 14
  • Breakdown:
  • 1 Sell Ratings
  • 6 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$78.65 As of 02/12/2026 05:00 PM ET
▼ -0.55 (-0.69%)

This chart shows the closing price for GEHC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New GE HealthCare Technologies Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GEHC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GEHC

Analyst Price Target is $92.50
▲ +17.61% Upside Potential
This price target is based on 14 analysts offering 12 month price targets for GE HealthCare Technologies in the last 3 months. The average price target is $92.50, with a high forecast of $105.00 and a low forecast of $77.00. The average price target represents a 17.61% upside from the last price of $78.65.

This chart shows the closing price for GEHC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 14 investment analysts is to hold stock in GE HealthCare Technologies. This rating changed within the last month from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 1 strong buy ratings
  • 6 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
8/21/2024
  • 1 strong buy ratings
  • 8 buy ratings
  • 5 hold ratings
  • 1 sell ratings
Ratings as of
11/19/2024
  • 1 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
2/17/2025
  • 1 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
5/18/2025
  • 0 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
8/16/2025
  • 0 strong buy ratings
  • 6 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
11/14/2025
  • 0 strong buy ratings
  • 7 buy ratings
  • 7 hold ratings
  • 0 sell ratings
Ratings as of
1/13/2026
  • 0 strong buy ratings
  • 7 buy ratings
  • 6 hold ratings
  • 1 sell ratings
Ratings as of
2/12/2026

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 6 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
2/6/2026BarclaysBoost TargetEqual Weight ➝ Equal Weight$86.00 ➝ $87.00
2/5/2026EvercoreBoost TargetOutperform ➝ Outperform$95.00 ➝ $98.00
2/5/2026Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$95.00 ➝ $97.00
2/4/2026Stifel NicolausBoost TargetBuy ➝ Buy$95.00 ➝ $98.00
2/4/2026Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$80.00 ➝ $85.00
2/4/2026BTIG ResearchBoost TargetBuy ➝ Buy$87.00 ➝ $91.00
1/30/2026Piper SandlerBoost TargetOverweight ➝ Overweight$91.00 ➝ $94.00
1/15/2026UBS GroupDowngradeNeutral ➝ Sell$73.00 ➝ $77.00
1/9/2026The Goldman Sachs GroupReiterated RatingBuy ➝ Buy$98.00
1/7/2026Stifel NicolausBoost TargetBuy ➝ Buy$90.00 ➝ $95.00
1/5/2026EvercoreReiterated RatingOutperform ➝ Outperform$95.00
1/5/2026Bank of AmericaBoost TargetNeutral ➝ Neutral$82.00 ➝ $92.00
12/29/2025Weiss RatingsReiterated RatingHold (C+) ➝ Hold (C+)
12/22/2025Weiss RatingsReiterated RatingHold (C+) ➝ Hold (C+)
12/15/2025Weiss RatingsReiterated RatingHold (C+) ➝ Hold (C+)
12/11/2025Jefferies Financial GroupBoost TargetBuy ➝ Buy$95.00 ➝ $105.00
12/11/2025CitigroupBoost TargetNeutral ➝ Neutral$83.00 ➝ $88.00
12/1/2025Weiss RatingsReiterated RatingHold (C) ➝ Hold (C)
11/21/2025Stifel NicolausSet Target$90.00
11/21/2025BTIG ResearchReiterated RatingBuy ➝ Buy$87.00
11/17/2025Weiss RatingsReiterated RatingHold (C+) ➝ Hold (C+)
11/11/2025Weiss RatingsReiterated RatingHold (C+) ➝ Hold (C+)
10/30/2025Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$89.00 ➝ $87.00
10/30/2025Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$74.00 ➝ $80.00
10/30/2025EvercoreBoost TargetOutperform ➝ Outperform$88.00 ➝ $92.00
10/29/2025BTIG ResearchSet Target$87.00
10/14/2025Weiss RatingsReiterated RatingHold (C+) ➝ Hold (C+)
10/13/2025BTIG ResearchBoost TargetBuy ➝ Buy$87.00 ➝ $89.00
10/13/2025BarclaysInitiated CoverageEqual Weight$86.00
10/13/2025BarclaysInitiated CoverageEqual Weight$86.00
10/7/2025CitigroupDowngradeBuy ➝ Neutral$93.00 ➝ $83.00
9/29/2025Zacks ResearchDowngradeStrong-Buy ➝ Hold
9/27/2025Weiss RatingsReiterated RatingHold (C) ➝ Hold (C)
9/18/2025Morgan StanleySet Target$74.00
8/28/2025Zacks ResearchUpgradeHold ➝ Strong-Buy
7/31/2025CitigroupBoost TargetBuy ➝ Buy$89.00 ➝ $93.00
7/31/2025Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$78.00 ➝ $74.00
7/14/2025BTIG ResearchReiterated RatingBuy ➝ Buy
7/9/2025CitigroupBoost TargetBuy ➝ Buy$86.00 ➝ $89.00
5/6/2025Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$86.00 ➝ $78.00
5/5/2025UBS GroupUpgradeSell ➝ Neutral$74.00 ➝ $73.00
5/1/2025The Goldman Sachs GroupLower TargetBuy ➝ Buy$94.00 ➝ $82.00
5/1/2025Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$103.00 ➝ $89.00
5/1/2025EvercoreLower TargetOutperform ➝ Outperform$96.00 ➝ $85.00
4/30/2025CitigroupLower TargetBuy ➝ Buy$105.00 ➝ $86.00
4/23/2025Piper SandlerLower TargetOverweight ➝ Overweight$104.00 ➝ $88.00
4/14/2025BTIG ResearchSet TargetBuy ➝ Buy$95.00
3/11/2025The Goldman Sachs GroupUpgradeNeutral ➝ Buy$85.00 ➝ $100.00
2/14/2025Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$96.00 ➝ $103.00
2/13/2025CitigroupBoost TargetBuy ➝ Buy$103.00 ➝ $110.00
1/8/2025Jefferies Financial GroupUpgradeHold ➝ Buy$95.00 ➝ $103.00
10/31/2024Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$95.00 ➝ $96.00
10/1/2024EvercoreBoost TargetOutperform ➝ Outperform$98.00 ➝ $102.00
9/30/2024Stifel NicolausBoost TargetBuy ➝ Buy$100.00 ➝ $102.00
9/26/2024UBS GroupDowngradeNeutral ➝ Sell$84.00 ➝ $74.00
9/18/2024BTIG ResearchUpgradeNeutral ➝ Buy$100.00
9/9/2024JPMorgan Chase & Co.Initiated CoverageNeutral$90.00
8/6/2024Stifel NicolausInitiated CoverageBuy$100.00
8/1/2024Rothschild & Co RedburnUpgradeStrong-Buy
5/30/2024The Goldman Sachs GroupInitiated CoverageNeutral$87.00
5/1/2024Bank of AmericaLower TargetNeutral ➝ Neutral$94.00 ➝ $86.00
5/1/2024MizuhoLower TargetBuy ➝ Buy$110.00 ➝ $105.00
4/11/2024MizuhoBoost TargetBuy ➝ Buy$96.00 ➝ $110.00
4/4/2024EvercoreBoost TargetOutperform ➝ Outperform$93.00 ➝ $100.00
4/3/2024CitigroupBoost TargetBuy ➝ Buy$88.00 ➝ $103.00
4/1/2024ArgusBoost TargetBuy ➝ Buy$80.00 ➝ $110.00
2/15/2024HSBCInitiated CoverageBuy$100.00
2/12/2024Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$74.00 ➝ $86.00
2/12/2024UBS GroupUpgradeSell ➝ Neutral$66.00 ➝ $88.00
2/7/2024MizuhoBoost TargetBuy ➝ Buy$94.00 ➝ $96.00
12/4/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$78.00 ➝ $74.00
11/30/2023Jefferies Financial GroupInitiated CoverageHold$80.00
11/27/2023UBS GroupDowngradeNeutral ➝ Sell$86.00 ➝ $66.00
9/19/2023CitigroupInitiated CoverageBuy$82.00
8/25/2023ArgusInitiated CoverageBuy$80.00
8/16/2023Wells Fargo & CompanyInitiated CoverageOverweight$90.00
7/31/2023Bank of AmericaInitiated CoverageNeutral$82.00
6/27/2023Morgan StanleyInitiated CoverageEqual Weight
5/15/2023OppenheimerInitiated CoverageOutperform$97.00
4/26/2023MizuhoBoost Target$92.00 ➝ $94.00
4/26/2023UBS GroupInitiated CoverageNeutral$86.00
4/19/2023Piper SandlerInitiated CoverageOverweight$95.00
4/18/2023MizuhoBoost Target$90.00 ➝ $92.00
4/10/2023BTIG ResearchInitiated CoverageNeutral
3/13/2023EvercoreInitiated CoverageOutperform$90.00
2/17/2023MizuhoInitiated CoverageBuy$90.00
1/19/2023Rothschild & Co RedburnInitiated CoverageBuy
1/4/2023Edward JonesInitiated CoverageHold
(Data available from 2/13/2021 forward)

News Sentiment Rating

1.04 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/18/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/17/2025
  • 75 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/16/2025
  • 44 very positive mentions
  • 23 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/16/2025
  • 74 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/15/2025
  • 92 very positive mentions
  • 17 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/15/2025
  • 25 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/14/2026
  • 41 very positive mentions
  • 20 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
2/13/2026

Current Sentiment

  • 41 very positive mentions
  • 20 positive mentions
  • 3 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

GE HealthCare Technologies logo
GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, image-guided therapy, X-ray systems, and women's health products. The Ultrasound segment provides medical devices and solutions for screening, diagnosis, treatment, and monitoring of certain diseases in clinical areas, such as radiology and primary care, women's health, cardiovascular, and point of care and handheld ultrasound solutions, as well as surgical visualization and guidance products. The Patient Care Solutions segment provides medical devices, consumables, services, and digital solutions. Its portfolio includes patient monitoring solutions, anesthesia delivery and respiratory care products, electrocardiogram solutions, maternal infant care products, and consumables and services. The Pharmaceutical Diagnostics supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, positron emission tomography, and ultrasound to the radiology and nuclear medicine industry. The segment also provides contrast media pharmaceuticals that are administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes. It has an AI collaboration with Mass General Brigham. The company was formerly known as GE Healthcare Holding LLC and changed its name to GE HealthCare Technologies Inc. in December 2022. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.
Read More

Today's Range

Now: $78.65
Low: $76.66
High: $79.83

50 Day Range

MA: $82.54
Low: $78.65
High: $88.16

52 Week Range

Now: $78.65
Low: $57.65
High: $94.80

Volume

3,849,564 shs

Average Volume

3,776,821 shs

Market Capitalization

$35.84 billion

P/E Ratio

17.25

Dividend Yield

0.18%

Beta

1.08

Frequently Asked Questions

What sell-side analysts currently cover shares of GE HealthCare Technologies?

The following Wall Street sell-side analysts have issued reports on GE HealthCare Technologies in the last twelve months: Bank of America Corporation, Barclays PLC, BTIG Research, Citigroup Inc., Evercore Inc, Jefferies Financial Group Inc., Morgan Stanley, Piper Sandler, Stifel Nicolaus, The Goldman Sachs Group, Inc., UBS Group AG, Wall Street Zen, Weiss Ratings, Wells Fargo & Company, and Zacks Research.
View the latest analyst ratings for GEHC.

What is the current price target for GE HealthCare Technologies?

0 Wall Street analysts have set twelve-month price targets for GE HealthCare Technologies in the last year. Their average twelve-month price target is $92.50, suggesting a possible upside of 17.6%. Jefferies Financial Group Inc. has the highest price target set, predicting GEHC will reach $105.00 in the next twelve months. UBS Group AG has the lowest price target set, forecasting a price of $77.00 for GE HealthCare Technologies in the next year.
View the latest price targets for GEHC.

What is the current consensus analyst rating for GE HealthCare Technologies?

GE HealthCare Technologies currently has 1 sell rating, 6 hold ratings and 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in GEHC, but not buy more shares or sell existing shares.
View the latest ratings for GEHC.

What other companies compete with GE HealthCare Technologies?

Other companies that are similar to GE HealthCare Technologies include Koninklijke Philips, Medline, Zimmer Biomet, Smith & Nephew SNATS and Solventum. Learn More about companies similar to GE HealthCare Technologies.

How do I contact GE HealthCare Technologies' investor relations team?

GE HealthCare Technologies' physical mailing address is 500 West Monroe Street, Chicago, IL 60661. The company's listed phone number is 833-735-1139 and its investor relations email address is [email protected]. The official website for GE HealthCare Technologies is www.gehealthcare.com. Learn More about contacing GE HealthCare Technologies investor relations.